Comparison of Budesonide/formoterol versus Fluticasone furoate/vilanterol as maintenance and reliever therapy for asthma control: a real-world observational study.

Autor: Huang WC; Division of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan., Cheng WC; Division of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan. wcchengdr@gmail.com.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. wcchengdr@gmail.com.; Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan. wcchengdr@gmail.com.; Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan. wcchengdr@gmail.com., Chen CY; Division of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan., Liao WC; Division of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan., Wu BR; Division of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.; Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.; Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan., Chen WC; Division of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.; Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.; Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan., Tu CY; Division of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan., Chen CH; Division of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan. hsnu758@gmail.com.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. hsnu758@gmail.com., Hsu WH; Division of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Jazyk: angličtina
Zdroj: BMC pulmonary medicine [BMC Pulm Med] 2024 Aug 01; Vol. 24 (1), pp. 374. Date of Electronic Publication: 2024 Aug 01.
DOI: 10.1186/s12890-024-03190-8
Abstrakt: Background: Previous studies have reported reduced acute exacerbation rates and improved symptom control in asthma patients treated using inhaled corticosteroids plus formoterol maintenance and reliever therapy (MART). Fluticasone furoate (FF) and vilanterol (VIL) also provide rapid bronchodilation and sustained anti-inflammatory effects, however no studies have investigated FF/VIL as MART for asthma control.
Methods: From October 1, 2021 to September 30, 2023, this retrospective study included asthma patients classified as step 3 or 4 according to the Global Initiative for Asthma guidelines, who were then divided into two groups. One group received BUD/FOR as MART, while the other received FF/VIL as MART. Pulmonary function tests, exacerbation rates, Asthma Control Test (ACT), fractional exhaled nitric oxide (FeNO) levels, and blood eosinophil counts were measured before and after 12 months of treatment.
Results: A total of 161 patients were included, of whom 36 received BUD/FOR twice daily as MART, and 125 received FF/VIL once daily as MART. After 12 months of treatment, the FF/VIL group showed a significant increase in ACT scores by 1.57 (p < 0.001), while the BUD/FOR group had an increase of 0.88 (p = 0.11). In terms of FeNO levels, the BUD/FOR group experienced a decline of -0.2 ppb (p = 0.98), whereas the FF/VIL group had a mild increase of + 0.8 ppb (p = 0.7). Notably, there was a significant difference in the change of FeNO between the two groups (∆ FeNO: -0.2 ppb in BUD/FOR; + 0.8 ppb in FF/VIL, p < 0.001). There were no significant alterations observed in FEV1, blood eosinophil count, or acute exacerbation decline in either group.
Conclusions: In the current study, patients treated with FF/VIL as MART showed improvements in ACT scores, while those treated with BUD/FOR as MART exhibited a reduction in FeNO levels. However, the difference between the two treatment groups did not reach clinical significance. Thus, FF/VIL as MART showed similar effectiveness to BUD/FOR as MART.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: